AstraZeneca plc (LSE:AZN) (STO:AZN) (NYSE:AZN) said on Saturday that clinical trials for the potential COVID-19 vaccine AZD1222 have resumed in the UK after clearance from safety authorities.
The investigational vaccine was developed by the University of Oxford and its spin-out company, Vaccitech. Trials were paused on 6 September after a report of dangerous side effects. However, the study participant who suffered the adverse effects had reportedly been suffering neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis, City A.M. reported.
The UK's Medicines Health Regulatory Authority (MHRA) has now confirmed that it is safe to resume the trials.
AstraZeneca has entered into agreements to supply almost three billion doses of the vaccine to governments across the world.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins